<DOC>
	<DOCNO>NCT01009502</DOCNO>
	<brief_summary>Sodium stibogluconate may stop growth cancer cell block enzymes need cell growth . This originally design phase I/II trial study side effect sodium stibogluconate well work treat patient myelodysplastic syndrome . Unfortunately , due funding issue , phase II portion never conduct .</brief_summary>
	<brief_title>Phase I/II Trial Sodium Stibogluconate Myelodysplastic Syndrome</brief_title>
	<detailed_description>Patients receive sodium stibogluconate IV 30 minute day 1-5 15-19 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . Patients respond treatment may continue therapy disease progression . Patients undergo bone marrow aspiration , biopsy , peripheral blood sample collection periodically correlative laboratory study . After completion study treatment , patient follow 8 week . The phase II portion trial never conduct due lack funding .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Antimony Sodium Gluconate</mesh_term>
	<criteria>Documented myelodysplastic syndrome ( MDS ) , include therapyrelated MDS Meets 1 follow criterion : Refractory prior azacitidine decitabine Did tolerate treatment azacitidine decitabine due cytopenias side effect Not candidate azacitidine decitabine due cytopenias medical condition would contraindicate nucleoside analogue Refused treatment azacitidine decitabine Life expectancy â‰¥ 16 week Not pregnant nursing No B12 deficiency , folate deficiency , pyridoxine responsive anemia confirm relevant laboratory test No prolongation QTc ventricular ectopic beat EKG No evidence cardiac disease No active infection AND afebrile More 21 day since prior azacitidine decitabine More 21 day since prior treatment MDS ( e.g. , thalidomide , valproic acid , agent part clinical trial ) Prior cytokine ( e.g. , erythropoietin , GCSF , GMCSF ) allow Prior chemotherapy and/or radiotherapy solid tumor lymphoma allow provided evidence active disease prior malignancy Prior treatment leukemia ( e.g. , acute myeloid leukemia , chronic myelogenous leukemia , acute lymphocytic leukemia , chronic lymphocytic leukemia ) Concurrent cytokine Concurrent antileukemic treatment , include bone marrow transplantation radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>